Oncology
Latest news
915 articles · 20 / page
De-escalating Management of N1b Papillary Thyroid Carcinoma: Are Total Thyroidectomy and RAI Mandatory for All?
A multicenter study challenges the mandatory use of total thyroidectomy and radioactive iodine in all patients with lateral neck metastasis (cN1b) papillary thyroid carcinoma, suggesting that lobectomy may offer comparable oncologic outcome
Thyroid Lobectomy and Neck Dissection Offer Comparable Survival to Total Thyroidectomy in Selected N1b Papillary Thyroid Carcinoma
A landmark propensity-matched study from Memorial Sloan Kettering Cancer Center demonstrates that thyroid lobectomy with neck dissection provides similar survival and recurrence outcomes to total thyroidectomy plus radioactive iodine for sp
Cyst Fluid Genomics Redefine Risk: Mixed-Type IPMNs Harbor Greater Malignant Potential Than Branch-Duct Variants
A large-scale cohort study demonstrates that mixed-type IPMNs have a three-fold higher prevalence of high-risk mutations compared to branch-duct variants, and that cyst fluid NGS provides superior diagnostic specificity over traditional cli
Occupation Matters: New Data Reveal Wide Disparities in US Cancer Mortality Among Working-Age Adults
A comprehensive population study of 450,453 deaths identifies specific occupations, including fishing, mining, and funeral services, with disproportionately high cancer mortality, suggesting a complex interplay of workplace exposures and st
Scaling Symptom Relief: EHR-Facilitated Collaborative Care Outperforms Surveillance Alone in Large-Scale Oncology Trial
The E2C2 trial demonstrates that integrating electronic health record (EHR)-facilitated collaborative care with symptom surveillance significantly reduces the burden of anxiety, depression, and fatigue in oncology patients compared to surve
Targeting MET Amplification: Vebreltinib Shows Robust Antitumor Activity in Advanced NSCLC
The Phase 2 KUNPENG trial demonstrates that vebreltinib, a selective MET inhibitor, achieves a 48.8% objective response rate in patients with MET-amplified advanced non-small-cell lung cancer, regardless of prior treatment history, offering
GLIAA Trial Results: Contrast-Enhanced MRI Remains the Gold Standard for Re-irradiation Planning in Recurrent Glioblastoma
The multicenter GLIAA trial demonstrated that FET-PET-guided target volume delineation for re-irradiation does not provide a progression-free survival benefit over standard contrast-enhanced T1-weighted MRI in patients with recurrent gliobl
Beyond Nodal Status: A New Risk Score Predicts Recurrence in Lymph Node-Negative Pancreatic Neuroendocrine Tumors
A multi-center study in JAMA Surgery introduces a validated 13-point risk score to identify recurrence risk in LN-negative PanNET patients, revealing that tumor size, grade, and lymphovascular invasion are critical prognostic drivers even w
Breaking the Data Silos: Why Sharing Clinical Trial Biospecimens Is Non-Negotiable for Cancer Care
A critical review of 29 breast cancer registrational trials reveals a significant gap in biomarker research dissemination, prompting a call for mandatory data and biospecimen sharing to accelerate personalized oncology and honor patient con
Pathologic Response Predicts Disease-Free Survival in Neoadjuvant Immunotherapy for Mucosal HNSCC
A meta-analysis of 11 trials shows that partial and major pathologic responses after neoadjuvant immunotherapy significantly correlate with improved disease-free survival in mucosal HNSCC, suggesting these metrics serve as viable surrogate
Preoperative Total Diet Replacement Safely Reduces Morbidity Risk and Preserves Muscle Mass in Colorectal Cancer Surgery
The CARE feasibility trial demonstrates that a preoperative low-energy total diet replacement program is safe and effective for colorectal cancer patients with excess weight. Significant weight loss was achieved without compromising lean mu
Shared Decision-Making with Otolaryngologists and Palliative Care Specialists Enhances Multidisciplinary Support in Advanced Oral Cavity Cancer
A prospective cohort study demonstrates that a structured shared decision-making (SOP) model significantly increases the utilization of multidisciplinary palliative care services for patients with stage IV oral cavity cancer, bridging the g
Standardizing the Digital Signal: How an Ontology of Early Warning Signs Can Predict Cytokine Release Syndrome
This article explores a landmark mixed-methods study establishing a digital biomarker ontology for the early detection of Cytokine Release Syndrome (CRS). By identifying core physiological markers, researchers aim to transform immunotherapy
Integrated Multidisciplinary Care Slashes Radiotherapy Interruptions in Head and Neck Cancer: Results from the SHINE-MDT Randomized Trial
A randomized clinical trial demonstrates that the SHINE-MDT framework significantly reduces radiotherapy interruptions and improves nutritional, psychological, and quality-of-life outcomes for patients with head and neck cancer, offering a
Streamlining Sarcoma Care: Five-Day Preoperative Radiation Matches Long-Term Efficacy of 5-Week Regimens
A Phase 2 clinical trial reveals that an ultrahypofractionated 5-day preoperative radiation regimen for high-risk soft tissue sarcoma provides durable local control and favorable late-term toxicity compared to the conventional 5-week course
AUC3 2025: Expert Consensus Roadmap for Renal Cell and Urinary Tract Cancer Care
The 2025 Advanced Urologic Cancer Consensus Conference (AUC3) issues practical, evidence‑informed expert recommendations on diagnosis, perioperative therapy, frontline and later‑line systemic sequencing, and special populations for RCC and
MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment
The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep
Fixed-Duration Therapy Challenging the Continuous Paradigm in Chronic Lymphocytic Leukemia: Insights from the CLL17 Trial
The Phase 3 CLL17 trial demonstrates that fixed-duration venetoclax-based regimens are noninferior to continuous ibrutinib in previously untreated CLL, offering deep molecular responses and comparable progression-free survival while allowin
Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia
Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patien
Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention
The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high ra
Browse by specialty
Open language-specific specialty feeds and department pages.